Global Next Generation Sequencing (NGS) Product Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
Global Next Generation Sequencing (NGS) Product Market: by Type (Consumables, Instruments, Software & Services), Application (Diagnostics, Drug Discovery, Biomarker Discovery, Agriculture & Animal Research, Forensics, Others), Distribution Channels (Direct Sales, Distributors & Resellers, Online Sales, Others), Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single Molecule Real-Time Sequencing, Nanopore Sequencing, Others), Organization Size (Small, Medium, Large) and By Global Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 27-07-2025 | Format: PDF | Report ID:12857 | Author: Mike
Global Next Generation Sequencing (NGS) Product Market Outlook 2025-2035
The global Next Generation Sequencing (NGS) product market is at the forefront of a genomics revolution, empowering research, diagnostics, and therapeutics with unprecedented speed and accuracy. NGS products include consumables, instruments, and software that enable large-scale sequencing of DNA and RNA. These technologies have seen broad adoption, driven by declining costs, enhanced accuracy, and expanding clinical and research applications—ranging from cancer diagnostics and drug discovery to forensics and agricultural biotechnology. Market growth is anticipated to accelerate between 2025 and 2035 as genomics continues to transform personalized medicine and life sciences. Leading companies, innovative startups, and robust distribution networks are collectively fueling the rise of NGS in both established and emerging markets.
Latest Market Dynamics
Key Drivers
Growing adoption of NGS in clinical diagnostics, especially for oncology and infectious disease identification, as leading diagnostic labs and hospitals globally ramp up investments. For instance,
has expanded its NGS diagnostic portfolio in partnership with major hospital chains in 2024.
Declining sequencing costs and advances in bioinformatics solutions are making NGS more accessible to medium and small laboratories, facilitating rapid research cycles and clinical deployment. Thermo Fisher Scientific's recent platform upgrades in 2024 have demonstrated further reductions in per-sample sequencing costs.
Key Trends
Expansion of clinical applications for NGS, including non-invasive prenatal testing, rare disease diagnostics, and large-scale oncology panels. In June 2024, Roche announced the launch of new comprehensive pan-cancer NGS panels targeted at early detection.
Integration of AI-driven data analysis and cloud computing with NGS workflows to accelerate data interpretation and enhance scalability. BGI Group has launched AI-powered software suites in 2024, significantly reducing NGS turnaround times in clinical labs.
Key Opportunities
Growing demand for NGS-based companion diagnostics and precision medicine solutions, as pharma partnerships with NGS providers increase. Agilent Technologies announced new companion diagnostic collaborations in July 2024, enhancing drug development pipelines.
Expansion into emerging markets in APAC, Latin America, and Africa, where healthcare modernization and research funding are driving NGS adoption. In August 2024, QIAGEN opened a major regional NGS center in India to address rising demand.
Key Challenges
Data privacy and regulatory hurdles hinder the full deployment of NGS in clinical settings, particularly across regions with evolving data protection frameworks. European markets are especially affected by evolving GDPR compliance requirements.
Standardization of NGS platforms and protocols remains a challenge, restricting reproducibility and large-scale integration. Laboratory customers have expressed concern over interoperability, prompting vendors like PacBio to lead standardization efforts since June 2024.
Key Restraints
High initial capital investment and operational complexity of NGS platforms limit adoption among small-scale and resource-limited organizations. Startups and academic labs face challenges despite the falling sequencing costs.
Shortage of skilled bioinformaticians and laboratory experts hampers efficient data interpretation, creating bottlenecks in NGS result delivery. PerkinElmer reported in 2024 an ongoing need for robust training programs to address this skills gap.
Global Next Generation Sequencing (NGS) Product Market Share by Type, 2025
In 2025, consumables represent the largest share of the NGS product market, accounting for nearly half of total revenues. This dominance is driven by their recurring usage in every sequencing run, supporting the rapid expansion of both clinical and research sequencing workflows. Instruments form the second largest segment, with ongoing investments in cutting-edge sequencing platforms across hospitals and research settings. Software & Services are rapidly gaining traction due to the surging need for advanced data analytics, pipeline automation, and cloud-based NGS solutions. Together, these segments highlight the comprehensive spectrum of demand across the global genomics ecosystem.
Global Next Generation Sequencing (NGS) Product Market Share by Application, 2025
Diagnostics dominate the application landscape for NGS products in 2025, propelled by the surging adoption of genetic testing, oncology sequencing panels, and infectious disease surveillance. Drug discovery also commands a significant portion, with pharmaceutical and biotech companies leveraging NGS for target identification and biomarker research. Biomarker discovery continues to expand as clinical research intensifies on personalized and stratified medicine. Other applications such as agriculture, animal research, and forensics, while smaller, are experiencing steady growth due to the broadening availability and scalability of NGS technologies.
Global NGS Product Market Revenue (USD Million), 2020-2035
The global NGS product market is projected to grow significantly from 2020 to 2035. In 2025, market revenue is estimated at USD 7,150 Million, accelerating as clinical genomics, personalized medicine, and research adoption intensify. By 2030, revenues are expected to surpass USD 15,600 Million, driven by expansion in oncology diagnostics, pharmaceuticals, and emerging markets. By 2035, industry size may reach approximately USD 29,400 Million, reflecting robust CAGR across all primary segments. This dynamic trajectory highlights the transformative potential of NGS in healthcare and life sciences worldwide.
Global NGS Product Market YOY Growth (%), 2020-2035
Year-over-year (YOY) growth for the global NGS product market demonstrates strong momentum, particularly between 2025 and 2030, as clinical and research adoption surges. YOY growth stands at 12% in 2025, climbing to 14.2% by 2030 due to the rapid integration of NGS into diagnostics and drug development. By 2035, market expansion slightly moderates but remains significant at 13.1%, indicating a sustained pace of innovation and commercialization. These trends underscore robust market confidence and ongoing advances in sequencing technologies and applications.
North America leads the global NGS product market in 2025, capturing over 39% share due to well-established healthcare infrastructure, major sequencing players, and large-scale investment in genomics. Europe follows closely at 31%, with increasing adoption in precision medicine and laboratory research. Asia-Pacific has emerged as a dynamic growth engine, holding 22% of the market, given rapid healthcare modernization and expanding genomics research funding. Other regions including Latin America, Middle East, and Africa collectively account for the remaining market share, reflecting gradual but steady adoption.
The NGS product market is characterized by the prominent presence of established global leaders and growing competition from innovative companies. Illumina, Inc. commands the largest share at 29%, attributed to its highly regarded sequencing platforms and global reach. Thermo Fisher Scientific holds a 21% share, strengthening its foothold with comprehensive solutions and recent platform launches. BGI Group, the top player from Asia, accounts for 15%, leveraging its AI-enhanced sequencing and partnerships. Key players like Roche, Agilent Technologies, and Oxford Nanopore make up the remaining share, illustrating a competitive landscape marked by continuous product innovation.
Academic and research institutions represent the primary buyers of NGS products in 2025, making up 35% of total purchases, owing to sustained investment in genomic studies and translational research. Hospitals and clinical labs account for 28% as genomic testing becomes integral to diagnostics. Pharma and biotech firms together constitute 21% of the market, leveraging NGS in drug development and companion diagnostics, while remaining demand comes from agricultural research, forensics, and contract research organizations.
Study Coverage
Metrics
Details
Years
2020-2035
Base Year
2025
Market Size
Revenue (USD Million)
Regions
North America, Europe, APAC, South America, Middle East, Africa
Segments
By Type (Consumables, Instruments, Software & Services, Sample Preparation Kits, Sequencing Reagents, Library Preparation Kits); By Application (Diagnostics, Drug Discovery, Biomarker Discovery, Agriculture & Animal Research, Forensics, Others); By Technology (Sequencing by Synthesis, Ion Semiconductor Sequencing, Single Molecule Real-Time Sequencing, Nanopore Sequencing, Pyrosequencing, Others); By Distribution Channels (Direct Sales, Distributors & Resellers, Online Sales, Third-party Vendors, Retail Pharmacies, Others); By Organization Size (Small, Medium, Large)
June 2024: Illumina launched the NovaSeq X Plus, delivering record throughput for population genomics initiatives.
July 2024: Agilent Technologies entered new partnerships for companion diagnostics with leading pharmaceutical companies.
August 2024: QIAGEN opened its largest APAC NGS R&D and service center in India.
August 2024: BGI Group introduced an AI-driven NGS data portal, reducing turnaround time by up to 60%.
September 2024: Thermo Fisher Scientific revealed its Ion Torrent Flex platform upgrade, lowering sample processing costs further.
Frequently Asked Questions
About the Author
Mike
Lead Industry Analyst
Mike is a Lead Industry Analyst specializing in market research, industry analysis, and business consulting across Consumers Goods. Mike brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Mike has helped organizations translate data into actionable growth strategies.
